<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4958">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03042390</url>
  </required_header>
  <id_info>
    <org_study_id>GESIDA 9316</org_study_id>
    <nct_id>NCT03042390</nct_id>
  </id_info>
  <brief_title>Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice</brief_title>
  <acronym>CoDAR</acronym>
  <official_title>Multicenter Retrospective Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion SEIMC-GESIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag, S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion SEIMC-GESIDA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective observational study of patients who have taken a regimen containing
      DRV / c at least 24 weeks prior to study initiation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 750 patients and will record data at 24 weeks. The study will also
      record data at 48 weeks for those patients whom these data are available
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Virological effectiveness data: Percentage of patients with undetectable viral load</measure>
    <time_frame>24 weeks</time_frame>
    <description>Virological effectiveness data at 24 weeks: Percentage of patients with undetectable viral load, defined as HIV RNA &lt;50 copies / m.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Virological effectiveness data: change in the number of CD4 + T cells at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in the number of CD4 + T cells at 24 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Virological effectiveness data: time to loss of virological efficacy.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Defined virological failure as two consecutive levels of HIV RNA &gt; 50 copies / mL or single HIV RNA ≥ 500 copies / mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological effectiveness data: Percentage of patients with undetectable viral load, defined as HIV RNA levels ≤ 50 copies / mL or limit of detection of the center, at 48 weeks</measure>
    <time_frame>48 weeks</time_frame>
    <description>Virological effectiveness data at 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological effectiveness data: change in the number of CD4 + T cells, at 48 weeks</measure>
    <time_frame>48 weeks</time_frame>
    <description>Virological effectiveness data at 48 weeks: change in the number of CD4 + T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the renal profile: Comparison of mean values of Creatinine and eFG (CKD-EPI).</measure>
    <time_frame>Basal and 24 weeks/48 weeks</time_frame>
    <description>Creatinine (mg/dl), eFG (CKD-EPI) (ml/min/1,73 m2),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the lipid profile: Comparison of mean values of total cholesterol values, Col LDL, Col HDL and TG.</measure>
    <time_frame>basal and 24 weeks/48 weeks</time_frame>
    <description>Units: mg/dl or mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the hepatic profile: comparison of mean values of GOT, GPT, FA, GGT and BrT</measure>
    <time_frame>basal and 24 weeks/48 weeks</time_frame>
    <description>GOT, GPT, FA, GGT in units: UI/l or μKat/l or mU/ml. BrT in units: mg/dl or micromol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability data:Rate of patients discontinuing treatment for toxicity.</measure>
    <time_frame>24 weeks/48 weeks</time_frame>
    <description>Toxicity to the treatment or virological failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability data: Rate of patients discontinuing treatment for virological failure at 24 weeks / 48 weeks</measure>
    <time_frame>24 weeks/48 weeks</time_frame>
    <description>Virological failure defined as two consecutive levels of HIV RNA &gt; 50 copies / mL or single HIV RNA ≥ 500 copies / mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients who develop any adverse effects:frequency of adverse events,frequency of serious adverse events, frequency of adverse events leading to discontinuation of treatment, number of deaths and frequency of laboratory abnormalities.</measure>
    <time_frame>24 weeks/48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Representative subgroups of patients according to the treatment that patient is taking: Percentage of patients with different Darunavir/cobicistat based regimens (Monotherapy, Bitherapy, triple Therapy, others)</measure>
    <time_frame>24 weeks / 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provenance treatments: Percentage of patients with different prior therapies (Darunavir Therapy, Other PI therapies, NNRTI based regimen, INI bases regimen</measure>
    <time_frame>24 weeks / 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for the change prior the initiation:Percentage of patients with each main reason to change to a DRV/c based regimen (first regimen, simplification, intolerance or toxicity, prior adherence problems, prior interactions, prior failure, others)</measure>
    <time_frame>24 weeks / 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>DArunavir/cobicistat</arm_group_label>
    <description>Patients starting treatment with a regimen containing Darunavir / cobicistat for at least 24 weeks</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        HIV patients that initiated treatment with a régimen containing DRV/c at least 24 weeks
        prior initiation of study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with HIV infection

          -  Inform consent document.

          -  To have initiated therapy containing DRV / c and have a follow-up of at least 24
             Weeks.

        Exclusion Criteria:

          -  Not having evaluable clinical data of the patient

          -  Patients not routinely followed in the center

          -  Patient less than 18 years of age.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Malaga</city>
        <state>Marbella</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Javier de la Torre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esteban Martinez, MD</last_name>
      <phone>0034 932275574</phone>
      <email>'esteban@fundsoriano.es'</email>
    </contact>
    <investigator>
      <last_name>Esteban Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mar Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hernando Knobel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Esteban Ribera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eugenia Negredo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Miguel Torralba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jesús Troya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Luz Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ignacio Santos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Príncipe de Asturias</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>José Sanz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alfonso Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Jesus Pérez Elías, MD</last_name>
      <phone>0034913368692</phone>
      <email>mjperez90@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mª Jesús Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jesús Santos, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antoni Payeras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Valme</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fernando Lozano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Toledo</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mª Antonia Sepúlveda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mª José GAlindo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marta Montero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalaria Alvaron Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Manuel Crespo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>February 1, 2017</lastchanged_date>
  <firstreceived_date>December 19, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cobicistat</mesh_term>
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
